{"gene":"RARA","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1998,"finding":"PML-RARα and PLZF-RARα both interact with nuclear receptor co-repressors (e.g., SMRT) and act as transcriptional repressors; PLZF-RARα additionally forms RA-insensitive co-repressor complexes via its PLZF moiety, explaining RA resistance. Histone deacetylase inhibitors (TSA) combined with RA can overcome repression by both fusion proteins, demonstrating that transcriptional silencing via HDAC recruitment is mechanistically central to APL pathogenesis.","method":"Transgenic mouse models, co-repressor interaction assays, transcriptional reporter assays, HDAC inhibitor rescue experiments","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction assays, transgenic models with defined phenotypic readout, replicated across two fusion protein variants with pharmacological rescue","pmids":["9462740"],"is_preprint":false},{"year":2008,"finding":"Arsenic-induced SUMOylation of the PML moiety of PML-RARα triggers Lys48-linked polyubiquitination and proteasome-dependent degradation via recruitment of RNF4 (the human SUMO-dependent E3 ubiquitin ligase). A non-degradable SUMOylation mutant of PML-RARα or dominant-negative RNF4 impairs arsenic-induced differentiation, directly implicating PML-RARα catabolism in therapeutic response.","method":"Co-immunoprecipitation, dominant-negative RNF4 transduction, SUMOylation mutant expression, proteasome inhibitor experiments, immunofluorescence of PML nuclear bodies","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (mutant rescue, dominant-negative, Co-IP, proteasome inhibition), clear mechanistic pathway established","pmids":["18408733"],"is_preprint":false},{"year":2001,"finding":"Endogenous RARα bidirectionally modulates granulopoiesis: it stimulates differentiation in the presence of retinoic acid and limits differentiation in the absence of ligand. RARα-deficient mice have a normal granulocyte population, showing RARα is modulatory rather than obligatory for neutrophil generation.","method":"RARα knockout mouse analysis, granulocyte differentiation assays, vitamin A-deficient mouse model, RAR antagonist treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with defined cellular phenotype, replicated across multiple model systems (KO mice, vitamin A deficiency, pharmacological antagonist)","pmids":["11222375"],"is_preprint":false},{"year":2008,"finding":"RARα associates with RNA-binding proteins (including Pur α and FMRP) in dendritic RNA transport granules in hippocampal neurons, binds mRNA (e.g., GluR1, CaMKIIα), inhibits translation initiation independent of cap or poly(A) tail, and redistributes mRNA to silencing ribonucleoprotein particles, providing a mechanism for rapid all-trans-retinoic acid-stimulated dendritic growth.","method":"LC/MS immunoaffinity isolation, tandem affinity purification, confocal microscopy, in vitro translation assay, RARα knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (MS, TAP, confocal, functional translation assay, KD) in a single study establishing non-transcriptional mechanism","pmids":["18495661"],"is_preprint":false},{"year":2006,"finding":"During RA-dependent activation, p38MAPK phosphorylates the coactivator SRC-3/AIB1 within RARα complexes; initial phosphorylation facilitates RARα-target gene activation, while subsequent phosphorylation promotes SRC-3 degradation and transcriptional inhibition. The RAR isotype dictates accessibility of SRC-3 to p38MAPK, defining an isotype-specific phosphorylation code.","method":"Phosphorylation assays, co-immunoprecipitation, p38MAPK inhibitor experiments, gene expression analysis, mutagenesis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro phosphorylation assays, mutagenesis, inhibitor rescue, multiple orthogonal approaches in single lab","pmids":["16456540"],"is_preprint":false},{"year":2006,"finding":"PML-RARα recruits MBD1 to target promoters through an HDAC3-mediated mechanism; HDAC3-MBD1 complex binding spreads across the locus. Knockdown of HDAC3 alleviates PML-RARα-induced promoter silencing, and dominant-negative MBD1 restores differentiation in hematopoietic precursors, demonstrating that the HDAC3-MBD1 complex is required for PML-RARα-mediated chromatin silencing.","method":"ChIP, RNA interference knockdown, retroviral dominant-negative expression, hematopoietic differentiation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, RNAi, dominant-negative rescue, multiple orthogonal methods establishing the HDAC3-MBD1 complex mechanism","pmids":["16432238"],"is_preprint":false},{"year":2006,"finding":"PML/RARα homodimerization (enforced by the PML moiety) enhances binding of the corepressor SMRT and dramatically extends the spectrum of DNA-binding sites compared to wild-type RARα. Both dimerization-induced SMRT binding and relaxed DNA-binding site specificity are required for efficient immortalization of primary hematopoietic progenitors.","method":"Mutagenesis of dimerization and DNA-binding domains, primary mouse hematopoietic progenitor immortalization assay, co-repressor binding assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutagenesis with functional rescue in primary cells, two independent mechanistic properties tested with defined outcomes","pmids":["16757557"],"is_preprint":false},{"year":2003,"finding":"ATRA treatment of PML-RARα-expressing APL cells induces a rapid increase in C/EBPβ protein and binding activity; PML-RARα directly transactivates the C/EBPβ promoter in an ATRA-dependent manner (PML-RARα transactivation mutants fail to do so). C/EBPβ induction is required for ATRA-induced granulocytic differentiation of APL cells.","method":"Transactivation reporter assays, Western blot, electrophoretic mobility shift assay, RNA interference, differentiation assays in NB4 cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reporter transactivation with mutant controls, RNAi functional rescue, multiple complementary approaches","pmids":["14592978"],"is_preprint":false},{"year":2013,"finding":"Uncoupled synthetic retinoids that activate PML/RARα-dependent transcription but fail to induce PML/RARα degradation elicit terminal differentiation but do not impair leukemia-initiating activity ex vivo or in vivo; differentiated cells sorted from uncoupled retinoid-treated mice retain PML/RARα and reinitiate APL upon transplant. This establishes that PML/RARα protein loss, not merely transcriptional activation, is required for APL eradication.","method":"Synthetic retinoid treatment, mouse APL transplantation model, ex vivo differentiation assays, secondary transplantation of sorted cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic/pharmacological dissection with mechanistic separation of transcriptional activation from proteolysis, secondary transplant validation","pmids":["23509325"],"is_preprint":false},{"year":2014,"finding":"Ablation of retinoid X receptor (RXRA) loosens PML/RARα DNA binding and induces terminal differentiation of APL cells ex vivo and in vivo; RXRA sumoylation contributes to PML/RARα-dependent transformation. APL differentiation is a default program triggered by clearance of PML/RARα from promoters, rather than requiring obligatory active transcriptional activation.","method":"RXRA ablation in APL cells (genetic), ex vivo and in vivo differentiation assays, transformation assay, sumoylation mutant analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation with defined mechanistic readout, sumoylation mutant, both ex vivo and in vivo validation","pmids":["25258343"],"is_preprint":false},{"year":2001,"finding":"PML interacts with co-repressors c-Ski, N-CoR, mSin3A and HDAC1, and this interaction is required for Mad-mediated transcriptional repression. PML-RARα has two co-repressor-binding sites and inhibits Mad-mediated repression by aberrantly binding co-repressor complexes, potentially dissociating them from their normal function.","method":"Co-immunoprecipitation, in vitro binding assays, luciferase reporter assays, dominant-negative approaches","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP in vitro and in vivo, reporter assays; single lab, no structural validation","pmids":["11430826"],"is_preprint":false},{"year":2002,"finding":"Stat5-RARα fusion protein represses transcription through the coiled-coil domain of Stat5 (aa 133-333), which mediates stable binding of the co-repressor SMRT independent of ATRA stimulation. Oligomerization via this domain blocks dissociation of co-repressors in response to ATRA, causing a differentiation block in hematopoietic cells.","method":"Reporter gene assays, domain deletion mutagenesis, co-repressor binding assays, hematopoietic differentiation assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis, co-repressor binding, functional differentiation assay; single lab","pmids":["11929749"],"is_preprint":false},{"year":2003,"finding":"RARα-mediated cell cycle arrest during granulocytic differentiation specifically requires both Mad1 and p27(Kip1); RARα does not directly regulate Mad1 or p27(Kip1), but the RARα target gene C/EBPε directly activates Mad1 transcription. ChIP confirmed direct binding of C/EBPε to the Mad1 promoter, establishing a RARα→C/EBPε→Mad1→p27 pathway for cell cycle arrest.","method":"Primary cells from p27(Kip1) and Mad1 knockout mice, RAR isoform-specific agonist treatment, chromatin immunoprecipitation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockouts, isoform-specific pharmacology, ChIP; multiple orthogonal approaches establishing pathway position","pmids":["14576045"],"is_preprint":false},{"year":2009,"finding":"PRKAR1A-RARα (R1A-RARα) fusion protein transforms bone marrow progenitor/stem cells and binds retinoic acid response elements as homodimer and heterodimer with RXRα. Leukemic transformation critically depends on RXRα: mutations in the RARα portion eliminating RXRα interaction, RXRα shRNA knockdown, or RXRα agonist treatment all reduce transformation capability. The RIIa domain is not required for transformation.","method":"Murine bone marrow retroviral transduction/transformation assay, gel-shift assays, point mutagenesis, shRNA knockdown, pharmacological RXRα activation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mutagenesis approaches, shRNA, pharmacological intervention, primary cell transformation assay","pmids":["19965660"],"is_preprint":false},{"year":2009,"finding":"p38αMAPK physically interacts with RARα in a ligand-independent manner, stabilizing RARα and PML-RARα by blocking their constitutive proteasomal degradation, thereby inhibiting ligand-dependent transactivation. Ser-369 in the E-region of RARα is essential for p38α binding and its functional inhibitory effects.","method":"Co-immunoprecipitation, mutagenesis (Ser-369), p38α pharmacological inhibition and gene silencing, transcriptional reporter assays, proliferation/differentiation assays","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, mutagenesis, siRNA, inhibitor; single lab with multiple complementary approaches","pmids":["22354283"],"is_preprint":false},{"year":2009,"finding":"RA suppresses CAK (CDK-activating kinase) phosphorylation of RARα at Ser77; mutation RARαS77A (phosphorylation-defective) coordinates G1 arrest with cancer cell differentiation. Hypophosphorylated RARα reduces binding to RARE in target gene promoters while stimulating gene transcription, accompanied by dissociation from transcriptional repressor N-CoR and association with coactivator NCoA-3.","method":"RARαS77A mutagenesis, chromatin immunoprecipitation, co-immunoprecipitation, xenograft tumor assay, gene expression analysis in myeloid leukemia and teratocarcinoma stem cells","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis, ChIP, Co-IP; single lab, multiple cell types tested","pmids":["19917671"],"is_preprint":false},{"year":2010,"finding":"RARα binds to the MMP-9 promoter in mammary gland cells during weaning, together with the coactivator p300, driving increased MMP-9 mRNA and protein expression. Administration of retinol palmitate to lactating rats also induces MMP-9 expression, demonstrating RARα-dependent transcriptional regulation of MMP-9 during mammary gland remodeling.","method":"Chromatin immunoprecipitation (ChIP), Western blot, zymography, in vivo retinol palmitate administration","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishes direct RARα-promoter binding with p300; in vivo corroboration; single lab","pmids":["17164434"],"is_preprint":false},{"year":2010,"finding":"RA treatment or RARαS77A (phosphorylation-defective mutant) expression inhibits proliferation and induces differentiation in U2OS osteosarcoma cells; FGF8f is identified as a downstream target induced by both RA and RARαS77A, and overexpression of FGF8f inhibits proliferation and induces osteoblastic differentiation markers, linking RA-suppressed RARα phosphorylation to a FGF8f-dependent differentiation pathway.","method":"RARαS77A mutagenesis, retroviral transduction, gene expression analysis, FGF8f overexpression, xenograft tumor assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with functional phenotypic readout and downstream target identification; single lab","pmids":["20190807"],"is_preprint":false},{"year":2002,"finding":"PML inhibits STAT3 activity by forming a complex with STAT3 through its B-box and C-terminal regions, inhibiting STAT3 DNA binding. PML-RARα does not interact with STAT3 but dissociates PML from STAT3, restoring STAT3 activity suppressed by PML. This leads to enhanced gp130-mediated growth when PML-RARα is expressed.","method":"Luciferase reporter assays, co-immunoprecipitation in vitro and in vivo, electrophoretic mobility shift assay, cytokine-dependent growth assays in Ba/F3 cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP in vitro and in vivo, EMSA, functional cell growth assays; single lab","pmids":["12506013"],"is_preprint":false},{"year":2007,"finding":"PML-RARα fusion protein activates ID1 and ID2 promoters (which wild-type RARα/RXR does not), through indirect interaction with Sp1 and NF-Y transcription factors without direct DNA binding, demonstrating a gain-of-function mechanism for the oncogenic fusion protein at a novel class of target genes.","method":"Reporter gene assays, ChIP, mutagenesis of DNA-binding domain, co-immunoprecipitation with Sp1 and NF-Y","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays, ChIP, Co-IP with transcription factors; single lab establishing indirect DNA interaction mechanism","pmids":["18025157"],"is_preprint":false},{"year":2010,"finding":"PML/RARα transactivates the tissue factor (TF) promoter through indirect interaction with a GAGC-containing element at position -230 to -242 without direct DNA association (EMSA showed no direct binding). AP-1 sites are dispensable for this regulation.","method":"Luciferase reporter assays with TF promoter deletion/mutation constructs, ChIP, EMSA","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis, ChIP, EMSA confirming absence of direct binding; single lab","pmids":["20133705"],"is_preprint":false},{"year":2008,"finding":"UBE1L (ubiquitin-activating enzyme E1-like) induces ISG15ylation of the PML domain of PML-RARα (not the RARα domain), causing its proteasomal degradation; RA treatment preferentially degrades the RARα domain of PML-RARα via a distinct pathway. USP18/UBP43 (ISG15 deconjugase) opposes UBE1L- but not RA-dependent PML-RARα degradation, confirming two independent degradation pathways converging on PML-RARα.","method":"Domain-specific transient transfection, ISG15ylation assay, proteasome inhibitor, USP18 deconjugase competition, domain mutagenesis","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mapping, ISG15 conjugation assay, deconjugase competition; single lab with multiple complementary experiments","pmids":["18413804"],"is_preprint":false},{"year":2015,"finding":"PML-RARA requires the methyltransferase activity of DNMT3A (but not DNMT3B) for aberrant self-renewal ex vivo, competitive transplantation advantage, and development of APL in vivo. DNMT3A is dispensable for RUNX1-RUNX1T1- and MLL-AF9-driven self-renewal, demonstrating a fusion-protein-specific epigenetic dependency.","method":"Retroviral expression of PML-RARA in DNMT3A-deficient mouse bone marrow cells, ex vivo self-renewal assays, competitive transplantation, Ctsg-PML-RARA transgenic mice on DNMT3A-null background","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple functional readouts (ex vivo, in vivo transplantation, leukemia development), fusion-specific controls included","pmids":["26595813"],"is_preprint":false},{"year":2011,"finding":"S100A3 calcium-binding protein directly interacts with RARα constitutively via the RARα ligand-binding domain (I396 residue is critical); this interaction controls the constitutive and ATRA-dependent degradation of RARα. In APL cells, S100A3 also interacts with PML-RARα; S100A3 knockdown decreases RARα levels and induces resistance to ATRA anti-proliferative effects in breast/lung cancer, while in APL/AML cells it increases basal and ATRA-induced differentiation.","method":"Co-immunoprecipitation, mutagenesis (I396), RARα interactome by LC-MS, knockdown and overexpression studies across multiple cell lines","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction confirmed by Co-IP and mutagenesis, functional consequences shown in multiple cell types; single lab","pmids":["30532072"],"is_preprint":false},{"year":2009,"finding":"TNIP1 interacts with liganded RARα and RARγ via its NR boxes and requires the AF-2 domain of the receptor (characteristic of coactivators), but functionally represses RAR activity; repression is partially relieved by SRC1, suggesting TNIP1 interferes with coactivator recruitment. TNIP1 preferential interaction with RARα over RARγ maps to RARα LBD helices 5-9.","method":"Co-immunoprecipitation, domain mutagenesis, reporter gene assay, SRC1 competition assay","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and reporter assay, single lab, limited mechanistic follow-up","pmids":["19732752"],"is_preprint":false},{"year":2014,"finding":"RARα forms a functional ternary complex with TDG (thymine DNA glycosylase) and CBP (histone acetylase). A TDG point mutation reducing ternary complex stability leads to deregulation of RA-target genes without affecting TDG's BER activity, demonstrating a direct coupling of TDG epigenomic function with RARα-dependent transcription.","method":"Co-immunoprecipitation, point mutagenesis of TDG, transcriptome profiling, reporter gene assay","journal":"Genomics, proteomics & bioinformatics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP and mutagenesis, global expression profiling; single lab, limited mechanistic depth","pmids":["24394593"],"is_preprint":false},{"year":2013,"finding":"RARα-PLZF (reciprocal fusion from t(11;17)) inhibits myeloid differentiation by interacting with C/EBPα tethered to DNA, recruiting HDAC1, and causing histone H3 deacetylation at C/EBPα target loci, thereby decreasing C/EBPα target gene expression. HDAC inhibitors partially restore C/EBPα target gene expression.","method":"ChIP, DNA capture assays, HDAC inhibitor rescue, Co-immunoprecipitation with C/EBPα, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, DNA capture, pharmacological rescue, Co-IP; multiple orthogonal methods in single lab","pmids":["23898169"],"is_preprint":false},{"year":2011,"finding":"PML-RARα enhances constitutive autophagy by inhibiting the Akt/mTOR pathway; this autophagic upregulation is specific to PML-RARα and not observed with PLZF-RARα or NPM-RARα. Autophagy contributes to the anti-apoptotic function of PML-RARα, and autophagic flux assay revealed increased on-rate of autophagic sequestration.","method":"Transmission electron microscopy, autophagic flux assay, 3-methyladenine inhibitor, Western blot for Akt/mTOR pathway, inducible PML-RARα expression, leukemic mouse model","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional readouts (TEM, flux assay, inhibitor, in vivo), pathway specificity confirmed with fusion protein comparisons; single lab","pmids":["21673516"],"is_preprint":false},{"year":2011,"finding":"Ligand-free RARα maintains epigenetic memory by regulating CpG methylation status at specific promoters (e.g., Mest, Tex13); RARα-KO cells show increased promoter CpG methylation and H3K9me3 at repressed genes, and decreased methylation with increased H3K9/K14ac at activated genes. Stable PML-RARα expression recapitulates the Mest downregulation seen in RARα-KO cells, and specific RARα/RXRα association with the Mest promoter was demonstrated.","method":"Microarray expression analysis, ChIP (H3K9me3, H3K9/K14ac, H3K4me3), bisulfite sequencing, RARα-KO cells, PML-RARα stable transfection, Co-IP of RARα/RXRα at Mest promoter","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and bisulfite sequencing with genetic KO and fusion protein; single lab, multiple epigenetic marks","pmids":["21911359"],"is_preprint":false},{"year":2017,"finding":"Intestinal epithelial cell-specific RARα signaling is required for proper epithelial lineage specification: RARα-deficient IECs show increased goblet cells and Paneth cells, increased KLF4+ goblet cell precursors, and an underdeveloped intestinal immune system (near-complete absence of lymphoid follicles and gut-resident mononuclear phagocytes). RA treatment inhibited klf4 expression and goblet cell differentiation in zebrafish, mechanistically linking RARα to KLF4 suppression.","method":"IEC-specific RARα conditional knockout mouse, zebrafish RA treatment/klf4 expression assay, histological analysis, infection clearance assay","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined cellular phenotype, zebrafish mechanistic validation; single lab","pmids":["29139475"],"is_preprint":false},{"year":2018,"finding":"Myeloid RARα protects against atherosclerosis by inducing cholesterol efflux transporter expression (Abca1, Abcg1) and inhibiting inflammation. Myeloid-specific RARα ablation reduces macrophage Abca1/Abcg1 expression and cholesterol efflux, increases inflammatory genes, and aggravates Western diet-induced atherosclerosis in Ldlr−/− mice.","method":"Myeloid-specific RARα conditional knockout (Rarα-flox × LysM-Cre), macrophage lipid accumulation assay, cholesterol efflux assay, atherosclerosis plaque quantitation, ATRA treatment","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined mechanistic and phenotypic readouts; single lab","pmids":["36291054"],"is_preprint":false},{"year":2018,"finding":"RARα supports Langerhans cell (LC) development from embryonic and bone marrow-derived progenitors by promoting expression of the LC-promoting transcription factor Runx3 and suppressing LC-inhibiting C/EBPβ. RARα promotes LC and langerin+ conventional DC development only under hypo-RA conditions, with this function suppressed at systemic RA levels.","method":"RARα conditional knockout, bone marrow-derived LC differentiation assays, Runx3 and C/EBPβ expression analysis, RA dose-response experiments","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO, defined transcription factor targets, RA dose-response; single lab","pmids":["30254197"],"is_preprint":false},{"year":2013,"finding":"PML-RARα acts through both repressive and activating transcriptional functions; the activating function involves recruiting P300 and forming super-enhancers. PML-RARα oligomers transactivate GFI1 through chromatin conformation changes at super-enhancers, and GFI1 is required for APL cell maintenance.","method":"ChIP-seq, Hi-C chromatin conformation, in vitro and in vivo functional assays, super-enhancer mapping","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq with super-enhancer mapping, chromatin conformation, functional in vivo validation; multiple orthogonal approaches","pmids":["32854112"],"is_preprint":false},{"year":2020,"finding":"PML-RARα mediates extensive chromatin interactions genome-wide, redefining chromatin topology toward a more condensed configuration in APL cells. Locally, PML-RARα intrudes RNAPII-associated interaction domains, interrupts myeloid-specific transcription factor binding at enhancers and super-enhancers, and leads to transcriptional repression of myeloid differentiation genes.","method":"3D genome/Hi-C analysis of inducible PML-RARα system and patient-derived APL cells, ChIP-seq, RNA-seq","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible system plus patient cells, 3D genome, ChIP-seq, RNA-seq; multiple orthogonal genome-wide methods","pmids":["32393309"],"is_preprint":false},{"year":2023,"finding":"p97/VCP segregase is required for arsenic-induced degradation of PML-RARA and PML. After arsenic treatment, p97 localizes to PML nuclear bodies and extracts poly-ubiquitinated, poly-SUMOylated PML for proteasomal degradation; UFD1 and NPLOC4 cofactors of p97 are critical for this process.","method":"Proteomics of PML bodies, pharmacological p97 inhibition, siRNA depletion of p97/UFD1/NPLOC4, immunofluorescence, Western blot, PML body morphology analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomics, pharmacological inhibition, siRNA, imaging; multiple orthogonal approaches establishing the UFD1-NPLOC4-p97 mechanism","pmids":["36880596"],"is_preprint":false},{"year":2023,"finding":"HDAC3 deacetylates PML-RARα at lysine 394, which reduces PIAS1-mediated PML-RARα SUMOylation and subsequent RNF4-induced ubiquitylation. HDAC3 inhibition promotes PML-RARα ubiquitylation and degradation in both wild-type and ATRA/ATO-resistant APL cells.","method":"Co-immunoprecipitation, deacetylation assay, SUMOylation assay, ubiquitylation assay, pharmacological HDAC3 inhibition, xenograft models, primary patient samples","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biochemical deacetylation/SUMOylation/ubiquitylation assays with site-specific mutant (K394), pharmacological and genetic validation in multiple models including patient samples","pmids":["36894687"],"is_preprint":false},{"year":2022,"finding":"PML/RARα is neddylated in its RARα moiety; neddylation enhances PML/RARα DNA-binding ability and impedes phase separation of the PML moiety, disrupting PML nuclear body assembly. Deneddylation of PML/RARα restores its phase separation and reconstructs functional PML nuclear bodies; MLN4924 (neddylation inhibitor) eradicates APL cells in vitro and in vivo.","method":"Neddylation assay, DNA-binding assay, phase separation imaging, PML nuclear body reconstitution, MLN4924 pharmacological inhibition, in vitro and in vivo APL models","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical and imaging assays, pharmacological validation in vivo; single lab, phase separation mechanistic claim requires further independent validation","pmids":["35194189"],"is_preprint":false},{"year":2020,"finding":"TRIB3 (pseudokinase) interacts with PML-RARα to inhibit PPARγ activity by disrupting the PPARγ/RXR interaction and promoting PPARγ degradation; reduced PPARγ activity in APL cells causes dyslipidemia. Arsenic/ATRA therapy degrades PML-RARα but elevates TRIB3, which then suppresses PPARγ/RXR dimerization, contributing to therapy-induced dyslipidemia.","method":"Co-immunoprecipitation, dual luciferase reporter assay, gene set enrichment analysis, Western blot, APL transgenic and transplantation mouse models, primary patient samples","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, reporter assay, multiple in vivo models; single lab","pmids":["32929351"],"is_preprint":false},{"year":2013,"finding":"PML-RARα phosphorylation by PKA blocks its ability to inhibit PML oligomerization and destabilize HIPK2 at nuclear bodies; PML oligomerization and HIPK2 stabilization at nuclear bodies are both required for APL cell differentiation.","method":"Nuclear body disruption assay, PML oligomerization assay, HIPK2 stability assay, PKA phosphorylation assay, APL cell differentiation assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical oligomerization and kinase assays with functional differentiation readout; single lab","pmids":["23722549"],"is_preprint":false},{"year":2021,"finding":"YOD1 deubiquitinase stabilizes PML/RARα by removing ubiquitin chains; siRNA-mediated YOD1 suppression promotes PML/RARα degradation and inhibits APL cells. The YOD1 inhibitor G5 degrades PML/RARα and eradicates APL cells including drug-resistant cells and patient-derived blasts.","method":"DUB siRNA library screen, siRNA knockdown of YOD1, ubiquitination assay, PML/RARα protein stability assay, APL cell and mouse model, primary patient blasts","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA screen, ubiquitination assay, in vivo validation; single lab","pmids":["35847510"],"is_preprint":false},{"year":2012,"finding":"USP37 deubiquitinase interacts with PLZF/RARA through the PLZF moiety and the N-terminal domain of USP37, sustaining PLZF/RARA steady-state levels by controlling its poly-ubiquitination. USP37 knockdown alleviates PLZF/RARA-mediated target gene suppression and cell transformation potential.","method":"RNAi screen, Co-immunoprecipitation, domain mapping, protein half-life assay, poly-ubiquitination assay, hematopoietic progenitor transformation assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi screen, Co-IP, half-life and ubiquitination assays, functional transformation assay; single lab","pmids":["23208507"],"is_preprint":false},{"year":2011,"finding":"PML-RARα directly represses S100A10 expression; ATRA-induced PML-RARα degradation rapidly downregulates S100A10 on the APL cell surface, reducing plasminogen receptor activity and fibrinolytic generation of plasmin at the cell surface. This provides a molecular link between PML-RARα expression and the hemorrhagic phenotype of APL.","method":"Flow cytometry for cell-surface S100A10, RNA interference knockdown of S100A10, inducible PML-RARα expression, fibrinolytic activity assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible expression, siRNA, functional fibrinolytic assay; single lab","pmids":["21310922"],"is_preprint":false},{"year":2002,"finding":"RAR alpha:RXR alpha heterodimers activate the rat Mrp2 (Abcc2) promoter; in obstructive cholestasis, cytokine (IL-1β)-dependent reduction of nuclear RAR alpha:RXR alpha levels and their binding to the Mrp2 promoter is associated with organ-specific suppression of hepatic Mrp2 expression while renal expression is preserved.","method":"Electrophoretic mobility shift assay (EMSA), immunoblot, ribonuclease protection assay, primary hepatocyte cytokine treatment, bile duct ligation model","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA demonstrating direct RARα:RXRα binding to Mrp2 promoter, in vivo and in vitro models; single lab","pmids":["12145812"],"is_preprint":false}],"current_model":"RARA encodes a ligand-activated nuclear receptor that, when bound to all-trans retinoic acid, heterodimerizes with RXRα to bind retinoic acid response elements and activate transcription of target genes driving myeloid differentiation, cell cycle arrest (via C/EBPε→Mad1→p27 axis), and tissue homeostasis; in the absence of ligand, RARα recruits co-repressors (SMRT, N-CoR, HDACs) to suppress target genes. In acute promyelocytic leukemia, fusion of RARα to PML (or other partners) enforces homodimerization, dramatically expands DNA-binding site repertoire, recruits co-repressors with higher affinity independent of RA, and recruits HDAC3-MBD1 complexes to establish stable epigenetic silencing of myeloid differentiation genes; therapeutic doses of RA or arsenic trioxide relieve repression and trigger proteasomal degradation of the fusion protein through distinct mechanisms—RA targets the RARα moiety and arsenic triggers SUMO-dependent RNF4-mediated polyubiquitination of the PML moiety, with subsequent p97/VCP-UFD1-NPLOC4 extraction for proteasomal destruction—and it is PML-RARα loss, not merely transcriptional reactivation, that eradicates leukemia-initiating cells. Beyond transcription, RARα also functions as a translational repressor in neuronal RNA granules and, through Ser77 phosphorylation by CAK, modulates the balance between transcriptional repression and activation during differentiation."},"narrative":{"mechanistic_narrative":"RARα is a ligand-activated nuclear receptor that heterodimerizes with RXRα on retinoic acid response elements to control gene programs of myeloid differentiation, cell-cycle arrest, and tissue homeostasis, acting bidirectionally to stimulate differentiation when bound to retinoic acid and to limit it in the unliganded state [PMID:11222375]. Mechanistically, RARα drives granulocytic cell-cycle arrest through a RARα→C/EBPε→Mad1→p27(Kip1) axis [PMID:14576045], and in the unliganded state maintains epigenetic memory by setting CpG methylation and histone-modification states at target promoters [PMID:21911359]. Tissue-specific signaling further governs intestinal epithelial lineage specification via KLF4 suppression [PMID:29139475], Langerhans cell development through Runx3 induction and C/EBPβ repression [PMID:30254197], and macrophage cholesterol efflux gene expression [PMID:36291054]. Beyond transcription, RARα associates with FMRP- and Purα-containing dendritic RNA transport granules, binds target mRNAs, and represses translation initiation independent of cap or poly(A) tail to drive retinoic-acid-stimulated dendritic growth [PMID:18495661]. RARα activity is tuned by phosphorylation: CAK phosphorylation at Ser77 shifts the balance toward repression, while its loss couples G1 arrest to differentiation through coactivator exchange (N-CoR off, NCoA-3 on) [PMID:19917671]. In acute promyelocytic leukemia, fusion of RARα to PML enforces homodimerization, which enhances corepressor (SMRT) binding and dramatically expands the DNA-binding site repertoire required for hematopoietic progenitor immortalization [PMID:16757557]; the fusion recruits HDAC3-MBD1 complexes to establish spreading chromatin silencing of differentiation genes [PMID:16432238] and additionally exerts P300-dependent activating functions through super-enhancer formation [PMID:32854112], reorganizing genome-wide chromatin topology toward a repressive configuration [PMID:32393309]. Therapeutic response depends on destruction of the fusion protein, not merely transcriptional reactivation [PMID:23509325]: retinoic acid targets the RARα moiety while arsenic triggers SUMO-dependent RNF4-mediated polyubiquitination of the PML moiety [PMID:18408733], with subsequent p97/VCP-UFD1-NPLOC4 extraction for proteasomal degradation [PMID:36880596].","teleology":[{"year":1998,"claim":"Established that the defining oncogenic lesion of APL acts by aberrant transcriptional repression, reframing the disease as an epigenetic differentiation block reversible by combining HDAC inhibition with retinoic acid.","evidence":"Transgenic mouse models with co-repressor interaction assays and HDAC inhibitor rescue for PML-RARα and PLZF-RARα","pmids":["9462740"],"confidence":"High","gaps":["Did not identify the specific HDAC-containing complexes or genomic targets","Mechanism of RA resistance only attributed to PLZF moiety, not molecularly resolved"]},{"year":2001,"claim":"Defined endogenous RARα as a modulatory rather than obligatory regulator of granulopoiesis, distinguishing its normal physiological role from the dominant block imposed by fusion proteins.","evidence":"RARα knockout mice, vitamin A-deficiency model, and RAR antagonist treatment with granulocyte differentiation assays","pmids":["11222375"],"confidence":"High","gaps":["Did not identify direct transcriptional targets driving the modulatory effect","Redundancy with other RAR isotypes not resolved"]},{"year":2003,"claim":"Mapped the cell-cycle arrest arm of RARα differentiation signaling to a defined transcription factor cascade, placing RARα upstream of an indirect C/EBPε→Mad1→p27 pathway.","evidence":"Primary cells from p27 and Mad1 knockout mice, isoform-specific agonists, and ChIP of C/EBPε at the Mad1 promoter","pmids":["14576045"],"confidence":"High","gaps":["Direct RARα target genes between RARα and C/EBPε not fully enumerated","Did not address contribution of this axis in fusion-driven leukemia"]},{"year":2006,"claim":"Resolved how PML-RARα homodimerization confers gain-of-function, showing it both enhances corepressor binding and relaxes DNA-site specificity to enable hematopoietic immortalization, and identified the HDAC3-MBD1 complex as the silencing effector.","evidence":"Dimerization/DNA-binding domain mutagenesis with primary progenitor immortalization, plus ChIP, RNAi and dominant-negative MBD1 rescue","pmids":["16757557","16432238"],"confidence":"High","gaps":["Full genomic catalog of expanded binding sites not defined at this stage","How HDAC3-MBD1 spreading is initiated and bounded unresolved"]},{"year":2008,"claim":"Established that arsenic therapy works by catabolizing the fusion protein, defining SUMOylation of the PML moiety and RNF4-mediated ubiquitination as the degradation trigger required for differentiation.","evidence":"Co-IP, non-degradable SUMO mutant, dominant-negative RNF4, and proteasome inhibition in APL cells","pmids":["18408733"],"confidence":"High","gaps":["Did not identify the segregase/extraction machinery downstream of ubiquitination","Relationship to the parallel RA-induced degradation pathway not addressed"]},{"year":2008,"claim":"Extended RARα function beyond transcription by identifying a translational repressor role in neuronal dendritic RNA granules, providing a mechanism for rapid retinoic-acid-stimulated dendritic growth.","evidence":"LC/MS immunoaffinity isolation, TAP, confocal microscopy, in vitro translation assays and RARα knockdown in hippocampal neurons","pmids":["18495661"],"confidence":"High","gaps":["Structural basis of RARα mRNA binding not defined","Generality across other neuronal mRNAs and cell types untested"]},{"year":2013,"claim":"Separated transcriptional reactivation from protein clearance, proving that PML-RARα degradation, not differentiation induction per se, is required to eradicate leukemia-initiating cells.","evidence":"Uncoupling synthetic retinoids in a mouse APL transplantation model with secondary transplantation of sorted differentiated cells","pmids":["23509325"],"confidence":"High","gaps":["Molecular basis distinguishing transcriptional from degradative activity of retinoids not detailed","Did not address whether arsenic-mediated clearance behaves identically"]},{"year":2014,"claim":"Demonstrated that APL differentiation is a default program released by clearing the fusion from chromatin, with RXRA required both for transformation and for the fusion's tight DNA binding.","evidence":"Genetic RXRA ablation with ex vivo and in vivo differentiation assays and sumoylation mutant analysis","pmids":["25258343"],"confidence":"High","gaps":["Mechanism by which RXRA loss loosens DNA binding not structurally defined","Role of RXRA sumoylation in transformation only partially mapped"]},{"year":2015,"claim":"Identified a fusion-protein-specific epigenetic dependency, showing PML-RARA uniquely requires DNMT3A methyltransferase activity for self-renewal and leukemogenesis.","evidence":"PML-RARA expression in DNMT3A-deficient bone marrow, competitive transplantation, and Ctsg-PML-RARA transgenic mice on DNMT3A-null background","pmids":["26595813"],"confidence":"High","gaps":["Specific DNMT3A target loci enforcing self-renewal not identified","Mechanistic link between DNMT3A and HDAC3-MBD1 silencing unexplored"]},{"year":2020,"claim":"Revealed that PML-RARα reshapes 3D genome topology and possesses an activating, super-enhancer-forming function alongside repression, broadening the oncogenic mechanism beyond simple corepressor recruitment.","evidence":"ChIP-seq, Hi-C and super-enhancer mapping in inducible and patient-derived APL cells with in vivo functional validation of GFI1","pmids":["32854112","32393309"],"confidence":"High","gaps":["How a single fusion both activates super-enhancers and represses differentiation loci mechanistically unresolved","Determinants of locus-specific activation versus repression not defined"]},{"year":2023,"claim":"Completed the arsenic-induced degradation pathway by identifying the p97/VCP segregase and its UFD1-NPLOC4 cofactors as the machinery that extracts ubiquitinated, SUMOylated PML-RARA from nuclear bodies for proteasomal destruction.","evidence":"PML-body proteomics, p97 pharmacological inhibition, siRNA depletion of p97/UFD1/NPLOC4, and imaging","pmids":["36880596"],"confidence":"High","gaps":["Whether p97 also participates in RA-induced RARα-moiety degradation untested","Stoichiometry and timing of extraction relative to RNF4 action unresolved"]},{"year":null,"claim":"It remains unresolved how the multiple post-translational modification systems controlling RARα/fusion stability (SUMO, ubiquitin, ISG15, NEDD8, acetylation, phosphorylation) are integrated and prioritized to determine therapeutic protein clearance.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model linking the competing modification pathways","Relative contribution of each pathway to durable leukemia eradication unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,6,12,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[6,13,16,28,42]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[3]},{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,28,34]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[5,6,32]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,12,32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[5,28,33]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,8,22]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,34,35]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,29,31]}],"complexes":["RARα-RXRα heterodimer","PML-RARα fusion oncoprotein","HDAC3-MBD1 corepressor complex"],"partners":["RXRA","PML","SMRT","HDAC3","NCOR2","FMRP","S100A3","EP300"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P10276","full_name":"Retinoic acid receptor alpha","aliases":["Nuclear receptor subfamily 1 group B member 1"],"length_aa":462,"mass_kda":50.8,"function":"Receptor for retinoic acid (PubMed:16417524, PubMed:19850744, PubMed:20215566, PubMed:21152046, PubMed:37478846). Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes (PubMed:21152046, PubMed:28167758, PubMed:37478846). The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (PubMed:19398580, PubMed:28167758). In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression (PubMed:16417524). On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation (PubMed:19850744, PubMed:20215566, PubMed:37478846, PubMed:9267036). Formation of a complex with histone deacetylases might lead to inhibition of RARE DNA element binding and to transcriptional repression (PubMed:28167758). Transcriptional activation and RARE DNA element binding might be supported by the transcription factor KLF2 (PubMed:28167758). RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis (By similarity). Has a role in the survival of early spermatocytes at the beginning prophase of meiosis (By similarity). In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes (By similarity). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Together with RXRA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells (PubMed:28167758). In association with HDAC3, HDAC5 and HDAC7 corepressors, plays a role in the repression of microRNA-10a and thereby promotes the inflammatory response (PubMed:28167758)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P10276/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RARA","classification":"Not Classified","n_dependent_lines":14,"n_total_lines":1208,"dependency_fraction":0.011589403973509934},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RARA","total_profiled":1310},"omim":[{"mim_id":"618764","title":"CDK2-ASSOCIATED CULLIN DOMAIN-CONTAINING PROTEIN 1; CACUL1","url":"https://www.omim.org/entry/618764"},{"mim_id":"618649","title":"HECT DOMAIN E3 UBIQUITIN PROTEIN LIGASE 1; HECTD1","url":"https://www.omim.org/entry/618649"},{"mim_id":"616477","title":"NUCLEAR RECEPTOR-BINDING FACTOR 2; NRBF2","url":"https://www.omim.org/entry/616477"},{"mim_id":"615354","title":"LIGAND-DEPENDENT NUCLEAR RECEPTOR-INTERACTING FACTOR 1; LRIF1","url":"https://www.omim.org/entry/615354"},{"mim_id":"614061","title":"OLFACTOMEDIN 4; OLFM4","url":"https://www.omim.org/entry/614061"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Actin filaments","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RARA"},"hgnc":{"alias_symbol":["RAR","NR1B1","RARalpha","RAR-alpha"],"prev_symbol":[]},"alphafold":{"accession":"P10276","domains":[{"cath_id":"3.30.50.10","chopping":"96-156","consensus_level":"high","plddt":94.4851,"start":96,"end":156},{"cath_id":"1.10.565.10","chopping":"181-413","consensus_level":"high","plddt":95.0433,"start":181,"end":413}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10276","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10276-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10276-F1-predicted_aligned_error_v6.png","plddt_mean":78.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RARA","jax_strain_url":"https://www.jax.org/strain/search?query=RARA"},"sequence":{"accession":"P10276","fasta_url":"https://rest.uniprot.org/uniprotkb/P10276.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10276/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10276"}},"corpus_meta":[{"pmid":"18408733","id":"PMC_18408733","title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18408733","citation_count":611,"is_preprint":false},{"pmid":"9462740","id":"PMC_9462740","title":"Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9462740","citation_count":488,"is_preprint":false},{"pmid":"9144232","id":"PMC_9144232","title":"Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9144232","citation_count":304,"is_preprint":false},{"pmid":"12060771","id":"PMC_12060771","title":"PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12060771","citation_count":257,"is_preprint":false},{"pmid":"11704847","id":"PMC_11704847","title":"Translocations of the RARalpha gene in acute promyelocytic leukemia.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11704847","citation_count":162,"is_preprint":false},{"pmid":"1317574","id":"PMC_1317574","title":"Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1317574","citation_count":155,"is_preprint":false},{"pmid":"14592978","id":"PMC_14592978","title":"C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14592978","citation_count":147,"is_preprint":false},{"pmid":"11430826","id":"PMC_11430826","title":"Role of PML and PML-RARalpha in Mad-mediated transcriptional repression.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11430826","citation_count":125,"is_preprint":false},{"pmid":"11222375","id":"PMC_11222375","title":"Positive and negative regulation of granulopoiesis by endogenous RARalpha.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11222375","citation_count":113,"is_preprint":false},{"pmid":"24344243","id":"PMC_24344243","title":"Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24344243","citation_count":112,"is_preprint":false},{"pmid":"1849030","id":"PMC_1849030","title":"RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia.","date":"1991","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1849030","citation_count":112,"is_preprint":false},{"pmid":"32182684","id":"PMC_32182684","title":"Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32182684","citation_count":111,"is_preprint":false},{"pmid":"8755574","id":"PMC_8755574","title":"Transgenic expression of PML/RARalpha impairs myelopoiesis.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8755574","citation_count":93,"is_preprint":false},{"pmid":"16432238","id":"PMC_16432238","title":"The methyl-CpG binding protein MBD1 is required for PML-RARalpha function.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16432238","citation_count":84,"is_preprint":false},{"pmid":"24720386","id":"PMC_24720386","title":"RARA fusion genes in acute promyelocytic leukemia: a review.","date":"2014","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24720386","citation_count":82,"is_preprint":false},{"pmid":"19808868","id":"PMC_19808868","title":"Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19808868","citation_count":79,"is_preprint":false},{"pmid":"18495661","id":"PMC_18495661","title":"The nuclear transcription factor RARalpha associates with neuronal RNA granules and suppresses translation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18495661","citation_count":76,"is_preprint":false},{"pmid":"11704846","id":"PMC_11704846","title":"Function of RARalpha during the maturation of neutrophils.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11704846","citation_count":74,"is_preprint":false},{"pmid":"23509325","id":"PMC_23509325","title":"Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23509325","citation_count":73,"is_preprint":false},{"pmid":"16456540","id":"PMC_16456540","title":"P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcription.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16456540","citation_count":68,"is_preprint":false},{"pmid":"32854112","id":"PMC_32854112","title":"A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32854112","citation_count":67,"is_preprint":false},{"pmid":"10673742","id":"PMC_10673742","title":"A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities.","date":"2000","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/10673742","citation_count":66,"is_preprint":false},{"pmid":"12145812","id":"PMC_12145812","title":"Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis.","date":"2002","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/12145812","citation_count":64,"is_preprint":false},{"pmid":"15103387","id":"PMC_15103387","title":"Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/15103387","citation_count":60,"is_preprint":false},{"pmid":"21310922","id":"PMC_21310922","title":"Regulation of S100A10 by the PML-RAR-α oncoprotein.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21310922","citation_count":60,"is_preprint":false},{"pmid":"7519122","id":"PMC_7519122","title":"PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7519122","citation_count":60,"is_preprint":false},{"pmid":"22923494","id":"PMC_22923494","title":"Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22923494","citation_count":58,"is_preprint":false},{"pmid":"21245861","id":"PMC_21245861","title":"Genome-wide functions of PML-RARα in acute promyelocytic leukaemia.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21245861","citation_count":51,"is_preprint":false},{"pmid":"1911341","id":"PMC_1911341","title":"Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype.","date":"1991","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/1911341","citation_count":50,"is_preprint":false},{"pmid":"16331271","id":"PMC_16331271","title":"Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16331271","citation_count":49,"is_preprint":false},{"pmid":"16757557","id":"PMC_16757557","title":"Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16757557","citation_count":46,"is_preprint":false},{"pmid":"29139475","id":"PMC_29139475","title":"Intestinal epithelial cell-specific RARα depletion results in aberrant epithelial cell homeostasis and underdeveloped immune system.","date":"2017","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29139475","citation_count":46,"is_preprint":false},{"pmid":"21911359","id":"PMC_21911359","title":"Epigenetic regulation by RARα maintains ligand-independent transcriptional activity.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21911359","citation_count":44,"is_preprint":false},{"pmid":"29921692","id":"PMC_29921692","title":"Recurrent RARB Translocations in Acute Promyelocytic Leukemia Lacking RARA Translocation.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29921692","citation_count":44,"is_preprint":false},{"pmid":"9103677","id":"PMC_9103677","title":"Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.","date":"1997","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9103677","citation_count":43,"is_preprint":false},{"pmid":"18413804","id":"PMC_18413804","title":"UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.","date":"2008","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18413804","citation_count":42,"is_preprint":false},{"pmid":"7628753","id":"PMC_7628753","title":"The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.","date":"1995","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/7628753","citation_count":39,"is_preprint":false},{"pmid":"23208507","id":"PMC_23208507","title":"The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23208507","citation_count":38,"is_preprint":false},{"pmid":"11929749","id":"PMC_11929749","title":"The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11929749","citation_count":38,"is_preprint":false},{"pmid":"14576045","id":"PMC_14576045","title":"Identification of the molecular requirements for an RAR alpha-mediated cell cycle arrest during granulocytic differentiation.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14576045","citation_count":37,"is_preprint":false},{"pmid":"26374632","id":"PMC_26374632","title":"PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells.","date":"2015","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26374632","citation_count":37,"is_preprint":false},{"pmid":"26595813","id":"PMC_26595813","title":"PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26595813","citation_count":35,"is_preprint":false},{"pmid":"21673516","id":"PMC_21673516","title":"PML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway.","date":"2011","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/21673516","citation_count":35,"is_preprint":false},{"pmid":"12464434","id":"PMC_12464434","title":"The retinoic acid receptors RARalpha and RARgamma are required for inner ear development.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/12464434","citation_count":35,"is_preprint":false},{"pmid":"36894687","id":"PMC_36894687","title":"Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/36894687","citation_count":34,"is_preprint":false},{"pmid":"22920668","id":"PMC_22920668","title":"Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.","date":"2012","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/22920668","citation_count":34,"is_preprint":false},{"pmid":"17929112","id":"PMC_17929112","title":"PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.","date":"2007","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17929112","citation_count":34,"is_preprint":false},{"pmid":"25300573","id":"PMC_25300573","title":"Enhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25300573","citation_count":34,"is_preprint":false},{"pmid":"12506013","id":"PMC_12506013","title":"Opposing effects of PML and PML/RAR alpha on STAT3 activity.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12506013","citation_count":33,"is_preprint":false},{"pmid":"25258343","id":"PMC_25258343","title":"Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25258343","citation_count":33,"is_preprint":false},{"pmid":"20190807","id":"PMC_20190807","title":"Retinoid-suppressed phosphorylation of RARalpha mediates the differentiation pathway of osteosarcoma cells.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20190807","citation_count":33,"is_preprint":false},{"pmid":"36477975","id":"PMC_36477975","title":"Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36477975","citation_count":32,"is_preprint":false},{"pmid":"26537301","id":"PMC_26537301","title":"Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26537301","citation_count":32,"is_preprint":false},{"pmid":"35847510","id":"PMC_35847510","title":"Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35847510","citation_count":31,"is_preprint":false},{"pmid":"31662438","id":"PMC_31662438","title":"MED12, TERT and RARA in fibroepithelial tumours of the breast.","date":"2019","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31662438","citation_count":30,"is_preprint":false},{"pmid":"15160934","id":"PMC_15160934","title":"The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.","date":"2004","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/15160934","citation_count":30,"is_preprint":false},{"pmid":"1337847","id":"PMC_1337847","title":"RARA and PML genes in acute promyelocytic leukemia.","date":"1992","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/1337847","citation_count":29,"is_preprint":false},{"pmid":"23898169","id":"PMC_23898169","title":"RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23898169","citation_count":29,"is_preprint":false},{"pmid":"32929351","id":"PMC_32929351","title":"PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32929351","citation_count":28,"is_preprint":false},{"pmid":"17164434","id":"PMC_17164434","title":"Retinoids induce MMP-9 expression through RARalpha during mammary gland remodeling.","date":"2006","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17164434","citation_count":28,"is_preprint":false},{"pmid":"15516979","id":"PMC_15516979","title":"The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15516979","citation_count":27,"is_preprint":false},{"pmid":"18025157","id":"PMC_18025157","title":"Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18025157","citation_count":24,"is_preprint":false},{"pmid":"19732752","id":"PMC_19732752","title":"Liganded RARalpha and RARgamma interact with but are repressed by TNIP1.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19732752","citation_count":23,"is_preprint":false},{"pmid":"35194189","id":"PMC_35194189","title":"Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35194189","citation_count":23,"is_preprint":false},{"pmid":"8136268","id":"PMC_8136268","title":"PML/RAR alpha fusion gene is expressed in both granuloid/macrophage and erythroid colonies in acute promyelocytic leukaemia.","date":"1993","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/8136268","citation_count":23,"is_preprint":false},{"pmid":"20861188","id":"PMC_20861188","title":"PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20861188","citation_count":22,"is_preprint":false},{"pmid":"25915942","id":"PMC_25915942","title":"MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25915942","citation_count":22,"is_preprint":false},{"pmid":"29530751","id":"PMC_29530751","title":"RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29530751","citation_count":22,"is_preprint":false},{"pmid":"24394593","id":"PMC_24394593","title":"A TDG/CBP/RARα ternary complex mediates the retinoic acid-dependent expression of DNA methylation-sensitive genes.","date":"2014","source":"Genomics, proteomics & bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/24394593","citation_count":22,"is_preprint":false},{"pmid":"12615055","id":"PMC_12615055","title":"Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12615055","citation_count":22,"is_preprint":false},{"pmid":"22354283","id":"PMC_22354283","title":"p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22354283","citation_count":22,"is_preprint":false},{"pmid":"21949697","id":"PMC_21949697","title":"Characterisation of genome-wide PLZF/RARA target genes.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21949697","citation_count":21,"is_preprint":false},{"pmid":"19965660","id":"PMC_19965660","title":"Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19965660","citation_count":21,"is_preprint":false},{"pmid":"19917671","id":"PMC_19917671","title":"Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation.","date":"2009","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/19917671","citation_count":21,"is_preprint":false},{"pmid":"20133705","id":"PMC_20133705","title":"PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20133705","citation_count":21,"is_preprint":false},{"pmid":"30532072","id":"PMC_30532072","title":"S100A3 a partner protein regulating the stability/activity of RARα and PML-RARα in cellular models of breast/lung cancer and acute myeloid leukemia.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30532072","citation_count":21,"is_preprint":false},{"pmid":"20155840","id":"PMC_20155840","title":"Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20155840","citation_count":21,"is_preprint":false},{"pmid":"33247976","id":"PMC_33247976","title":"RecA-independent recombination: Dependence on the Escherichia coli RarA protein.","date":"2020","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33247976","citation_count":20,"is_preprint":false},{"pmid":"32393309","id":"PMC_32393309","title":"Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia.","date":"2020","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/32393309","citation_count":20,"is_preprint":false},{"pmid":"27012866","id":"PMC_27012866","title":"LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27012866","citation_count":20,"is_preprint":false},{"pmid":"30536958","id":"PMC_30536958","title":"PML/RARA inhibits expression of HSP90 and its target AKT.","date":"2018","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30536958","citation_count":19,"is_preprint":false},{"pmid":"36291054","id":"PMC_36291054","title":"Retinoic Acid Receptor Alpha (RARα) in Macrophages Protects from Diet-Induced Atherosclerosis in Mice.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36291054","citation_count":19,"is_preprint":false},{"pmid":"31126665","id":"PMC_31126665","title":"Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.","date":"2019","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31126665","citation_count":19,"is_preprint":false},{"pmid":"30254197","id":"PMC_30254197","title":"RARα supports the development of Langerhans cells and langerin-expressing conventional dendritic cells.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30254197","citation_count":19,"is_preprint":false},{"pmid":"11172538","id":"PMC_11172538","title":"Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.","date":"2001","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11172538","citation_count":19,"is_preprint":false},{"pmid":"27626703","id":"PMC_27626703","title":"PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626703","citation_count":18,"is_preprint":false},{"pmid":"36880596","id":"PMC_36880596","title":"The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.","date":"2023","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36880596","citation_count":17,"is_preprint":false},{"pmid":"33069074","id":"PMC_33069074","title":"Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review.","date":"2020","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33069074","citation_count":17,"is_preprint":false},{"pmid":"30674964","id":"PMC_30674964","title":"SP1 and RARα regulate AGAP2 expression in cancer.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30674964","citation_count":16,"is_preprint":false},{"pmid":"36759620","id":"PMC_36759620","title":"Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36759620","citation_count":16,"is_preprint":false},{"pmid":"18619947","id":"PMC_18619947","title":"Changes in the expression and subcellular localization of RARalpha in the rat hippocampus during postnatal development.","date":"2008","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/18619947","citation_count":16,"is_preprint":false},{"pmid":"11149416","id":"PMC_11149416","title":"Expression of RARalpha and RARbeta in human oral potentially malignant and neoplastic lesions.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11149416","citation_count":16,"is_preprint":false},{"pmid":"35639830","id":"PMC_35639830","title":"Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual-color dual-fusion FISH studies.","date":"2022","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35639830","citation_count":16,"is_preprint":false},{"pmid":"34042280","id":"PMC_34042280","title":"Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.","date":"2021","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34042280","citation_count":15,"is_preprint":false},{"pmid":"23722549","id":"PMC_23722549","title":"PML-RARα and its phosphorylation regulate pml oligomerization and HIPK2 stability.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23722549","citation_count":15,"is_preprint":false},{"pmid":"37451490","id":"PMC_37451490","title":"Kuijieling decoction regulates the Treg/Th17 cell balance in ulcerative colitis through the RA/RARα signaling pathway.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37451490","citation_count":15,"is_preprint":false},{"pmid":"12529666","id":"PMC_12529666","title":"C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12529666","citation_count":15,"is_preprint":false},{"pmid":"34936656","id":"PMC_34936656","title":"The rarA gene as part of an expanded RecFOR recombination pathway: Negative epistasis and synthetic lethality with ruvB, recG, and recQ.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34936656","citation_count":15,"is_preprint":false},{"pmid":"29947798","id":"PMC_29947798","title":"Bacillus subtilis RarA modulates replication restart.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29947798","citation_count":14,"is_preprint":false},{"pmid":"28053120","id":"PMC_28053120","title":"DNA flap creation by the RarA/MgsA protein of Escherichia coli.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28053120","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49457,"output_tokens":11287,"usd":0.158838,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":45936,"output_tokens":10361,"usd":0.356395,"resynth_parse_fail":true,"stage2_stop_reason":"end_turn"},"total_usd":0.515233,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"PML-RARα and PLZF-RARα both interact with nuclear receptor co-repressors (e.g., SMRT) and act as transcriptional repressors; PLZF-RARα additionally forms RA-insensitive co-repressor complexes via its PLZF moiety, explaining RA resistance. Histone deacetylase inhibitors (TSA) combined with RA can overcome repression by both fusion proteins, demonstrating that transcriptional silencing via HDAC recruitment is mechanistically central to APL pathogenesis.\",\n      \"method\": \"Transgenic mouse models, co-repressor interaction assays, transcriptional reporter assays, HDAC inhibitor rescue experiments\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction assays, transgenic models with defined phenotypic readout, replicated across two fusion protein variants with pharmacological rescue\",\n      \"pmids\": [\"9462740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Arsenic-induced SUMOylation of the PML moiety of PML-RARα triggers Lys48-linked polyubiquitination and proteasome-dependent degradation via recruitment of RNF4 (the human SUMO-dependent E3 ubiquitin ligase). A non-degradable SUMOylation mutant of PML-RARα or dominant-negative RNF4 impairs arsenic-induced differentiation, directly implicating PML-RARα catabolism in therapeutic response.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative RNF4 transduction, SUMOylation mutant expression, proteasome inhibitor experiments, immunofluorescence of PML nuclear bodies\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (mutant rescue, dominant-negative, Co-IP, proteasome inhibition), clear mechanistic pathway established\",\n      \"pmids\": [\"18408733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Endogenous RARα bidirectionally modulates granulopoiesis: it stimulates differentiation in the presence of retinoic acid and limits differentiation in the absence of ligand. RARα-deficient mice have a normal granulocyte population, showing RARα is modulatory rather than obligatory for neutrophil generation.\",\n      \"method\": \"RARα knockout mouse analysis, granulocyte differentiation assays, vitamin A-deficient mouse model, RAR antagonist treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with defined cellular phenotype, replicated across multiple model systems (KO mice, vitamin A deficiency, pharmacological antagonist)\",\n      \"pmids\": [\"11222375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RARα associates with RNA-binding proteins (including Pur α and FMRP) in dendritic RNA transport granules in hippocampal neurons, binds mRNA (e.g., GluR1, CaMKIIα), inhibits translation initiation independent of cap or poly(A) tail, and redistributes mRNA to silencing ribonucleoprotein particles, providing a mechanism for rapid all-trans-retinoic acid-stimulated dendritic growth.\",\n      \"method\": \"LC/MS immunoaffinity isolation, tandem affinity purification, confocal microscopy, in vitro translation assay, RARα knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (MS, TAP, confocal, functional translation assay, KD) in a single study establishing non-transcriptional mechanism\",\n      \"pmids\": [\"18495661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"During RA-dependent activation, p38MAPK phosphorylates the coactivator SRC-3/AIB1 within RARα complexes; initial phosphorylation facilitates RARα-target gene activation, while subsequent phosphorylation promotes SRC-3 degradation and transcriptional inhibition. The RAR isotype dictates accessibility of SRC-3 to p38MAPK, defining an isotype-specific phosphorylation code.\",\n      \"method\": \"Phosphorylation assays, co-immunoprecipitation, p38MAPK inhibitor experiments, gene expression analysis, mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro phosphorylation assays, mutagenesis, inhibitor rescue, multiple orthogonal approaches in single lab\",\n      \"pmids\": [\"16456540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PML-RARα recruits MBD1 to target promoters through an HDAC3-mediated mechanism; HDAC3-MBD1 complex binding spreads across the locus. Knockdown of HDAC3 alleviates PML-RARα-induced promoter silencing, and dominant-negative MBD1 restores differentiation in hematopoietic precursors, demonstrating that the HDAC3-MBD1 complex is required for PML-RARα-mediated chromatin silencing.\",\n      \"method\": \"ChIP, RNA interference knockdown, retroviral dominant-negative expression, hematopoietic differentiation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, RNAi, dominant-negative rescue, multiple orthogonal methods establishing the HDAC3-MBD1 complex mechanism\",\n      \"pmids\": [\"16432238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PML/RARα homodimerization (enforced by the PML moiety) enhances binding of the corepressor SMRT and dramatically extends the spectrum of DNA-binding sites compared to wild-type RARα. Both dimerization-induced SMRT binding and relaxed DNA-binding site specificity are required for efficient immortalization of primary hematopoietic progenitors.\",\n      \"method\": \"Mutagenesis of dimerization and DNA-binding domains, primary mouse hematopoietic progenitor immortalization assay, co-repressor binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutagenesis with functional rescue in primary cells, two independent mechanistic properties tested with defined outcomes\",\n      \"pmids\": [\"16757557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ATRA treatment of PML-RARα-expressing APL cells induces a rapid increase in C/EBPβ protein and binding activity; PML-RARα directly transactivates the C/EBPβ promoter in an ATRA-dependent manner (PML-RARα transactivation mutants fail to do so). C/EBPβ induction is required for ATRA-induced granulocytic differentiation of APL cells.\",\n      \"method\": \"Transactivation reporter assays, Western blot, electrophoretic mobility shift assay, RNA interference, differentiation assays in NB4 cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reporter transactivation with mutant controls, RNAi functional rescue, multiple complementary approaches\",\n      \"pmids\": [\"14592978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Uncoupled synthetic retinoids that activate PML/RARα-dependent transcription but fail to induce PML/RARα degradation elicit terminal differentiation but do not impair leukemia-initiating activity ex vivo or in vivo; differentiated cells sorted from uncoupled retinoid-treated mice retain PML/RARα and reinitiate APL upon transplant. This establishes that PML/RARα protein loss, not merely transcriptional activation, is required for APL eradication.\",\n      \"method\": \"Synthetic retinoid treatment, mouse APL transplantation model, ex vivo differentiation assays, secondary transplantation of sorted cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic/pharmacological dissection with mechanistic separation of transcriptional activation from proteolysis, secondary transplant validation\",\n      \"pmids\": [\"23509325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ablation of retinoid X receptor (RXRA) loosens PML/RARα DNA binding and induces terminal differentiation of APL cells ex vivo and in vivo; RXRA sumoylation contributes to PML/RARα-dependent transformation. APL differentiation is a default program triggered by clearance of PML/RARα from promoters, rather than requiring obligatory active transcriptional activation.\",\n      \"method\": \"RXRA ablation in APL cells (genetic), ex vivo and in vivo differentiation assays, transformation assay, sumoylation mutant analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation with defined mechanistic readout, sumoylation mutant, both ex vivo and in vivo validation\",\n      \"pmids\": [\"25258343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PML interacts with co-repressors c-Ski, N-CoR, mSin3A and HDAC1, and this interaction is required for Mad-mediated transcriptional repression. PML-RARα has two co-repressor-binding sites and inhibits Mad-mediated repression by aberrantly binding co-repressor complexes, potentially dissociating them from their normal function.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, luciferase reporter assays, dominant-negative approaches\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP in vitro and in vivo, reporter assays; single lab, no structural validation\",\n      \"pmids\": [\"11430826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Stat5-RARα fusion protein represses transcription through the coiled-coil domain of Stat5 (aa 133-333), which mediates stable binding of the co-repressor SMRT independent of ATRA stimulation. Oligomerization via this domain blocks dissociation of co-repressors in response to ATRA, causing a differentiation block in hematopoietic cells.\",\n      \"method\": \"Reporter gene assays, domain deletion mutagenesis, co-repressor binding assays, hematopoietic differentiation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis, co-repressor binding, functional differentiation assay; single lab\",\n      \"pmids\": [\"11929749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RARα-mediated cell cycle arrest during granulocytic differentiation specifically requires both Mad1 and p27(Kip1); RARα does not directly regulate Mad1 or p27(Kip1), but the RARα target gene C/EBPε directly activates Mad1 transcription. ChIP confirmed direct binding of C/EBPε to the Mad1 promoter, establishing a RARα→C/EBPε→Mad1→p27 pathway for cell cycle arrest.\",\n      \"method\": \"Primary cells from p27(Kip1) and Mad1 knockout mice, RAR isoform-specific agonist treatment, chromatin immunoprecipitation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockouts, isoform-specific pharmacology, ChIP; multiple orthogonal approaches establishing pathway position\",\n      \"pmids\": [\"14576045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PRKAR1A-RARα (R1A-RARα) fusion protein transforms bone marrow progenitor/stem cells and binds retinoic acid response elements as homodimer and heterodimer with RXRα. Leukemic transformation critically depends on RXRα: mutations in the RARα portion eliminating RXRα interaction, RXRα shRNA knockdown, or RXRα agonist treatment all reduce transformation capability. The RIIa domain is not required for transformation.\",\n      \"method\": \"Murine bone marrow retroviral transduction/transformation assay, gel-shift assays, point mutagenesis, shRNA knockdown, pharmacological RXRα activation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mutagenesis approaches, shRNA, pharmacological intervention, primary cell transformation assay\",\n      \"pmids\": [\"19965660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p38αMAPK physically interacts with RARα in a ligand-independent manner, stabilizing RARα and PML-RARα by blocking their constitutive proteasomal degradation, thereby inhibiting ligand-dependent transactivation. Ser-369 in the E-region of RARα is essential for p38α binding and its functional inhibitory effects.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis (Ser-369), p38α pharmacological inhibition and gene silencing, transcriptional reporter assays, proliferation/differentiation assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, mutagenesis, siRNA, inhibitor; single lab with multiple complementary approaches\",\n      \"pmids\": [\"22354283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RA suppresses CAK (CDK-activating kinase) phosphorylation of RARα at Ser77; mutation RARαS77A (phosphorylation-defective) coordinates G1 arrest with cancer cell differentiation. Hypophosphorylated RARα reduces binding to RARE in target gene promoters while stimulating gene transcription, accompanied by dissociation from transcriptional repressor N-CoR and association with coactivator NCoA-3.\",\n      \"method\": \"RARαS77A mutagenesis, chromatin immunoprecipitation, co-immunoprecipitation, xenograft tumor assay, gene expression analysis in myeloid leukemia and teratocarcinoma stem cells\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis, ChIP, Co-IP; single lab, multiple cell types tested\",\n      \"pmids\": [\"19917671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RARα binds to the MMP-9 promoter in mammary gland cells during weaning, together with the coactivator p300, driving increased MMP-9 mRNA and protein expression. Administration of retinol palmitate to lactating rats also induces MMP-9 expression, demonstrating RARα-dependent transcriptional regulation of MMP-9 during mammary gland remodeling.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), Western blot, zymography, in vivo retinol palmitate administration\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishes direct RARα-promoter binding with p300; in vivo corroboration; single lab\",\n      \"pmids\": [\"17164434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RA treatment or RARαS77A (phosphorylation-defective mutant) expression inhibits proliferation and induces differentiation in U2OS osteosarcoma cells; FGF8f is identified as a downstream target induced by both RA and RARαS77A, and overexpression of FGF8f inhibits proliferation and induces osteoblastic differentiation markers, linking RA-suppressed RARα phosphorylation to a FGF8f-dependent differentiation pathway.\",\n      \"method\": \"RARαS77A mutagenesis, retroviral transduction, gene expression analysis, FGF8f overexpression, xenograft tumor assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with functional phenotypic readout and downstream target identification; single lab\",\n      \"pmids\": [\"20190807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PML inhibits STAT3 activity by forming a complex with STAT3 through its B-box and C-terminal regions, inhibiting STAT3 DNA binding. PML-RARα does not interact with STAT3 but dissociates PML from STAT3, restoring STAT3 activity suppressed by PML. This leads to enhanced gp130-mediated growth when PML-RARα is expressed.\",\n      \"method\": \"Luciferase reporter assays, co-immunoprecipitation in vitro and in vivo, electrophoretic mobility shift assay, cytokine-dependent growth assays in Ba/F3 cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP in vitro and in vivo, EMSA, functional cell growth assays; single lab\",\n      \"pmids\": [\"12506013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PML-RARα fusion protein activates ID1 and ID2 promoters (which wild-type RARα/RXR does not), through indirect interaction with Sp1 and NF-Y transcription factors without direct DNA binding, demonstrating a gain-of-function mechanism for the oncogenic fusion protein at a novel class of target genes.\",\n      \"method\": \"Reporter gene assays, ChIP, mutagenesis of DNA-binding domain, co-immunoprecipitation with Sp1 and NF-Y\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays, ChIP, Co-IP with transcription factors; single lab establishing indirect DNA interaction mechanism\",\n      \"pmids\": [\"18025157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PML/RARα transactivates the tissue factor (TF) promoter through indirect interaction with a GAGC-containing element at position -230 to -242 without direct DNA association (EMSA showed no direct binding). AP-1 sites are dispensable for this regulation.\",\n      \"method\": \"Luciferase reporter assays with TF promoter deletion/mutation constructs, ChIP, EMSA\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis, ChIP, EMSA confirming absence of direct binding; single lab\",\n      \"pmids\": [\"20133705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"UBE1L (ubiquitin-activating enzyme E1-like) induces ISG15ylation of the PML domain of PML-RARα (not the RARα domain), causing its proteasomal degradation; RA treatment preferentially degrades the RARα domain of PML-RARα via a distinct pathway. USP18/UBP43 (ISG15 deconjugase) opposes UBE1L- but not RA-dependent PML-RARα degradation, confirming two independent degradation pathways converging on PML-RARα.\",\n      \"method\": \"Domain-specific transient transfection, ISG15ylation assay, proteasome inhibitor, USP18 deconjugase competition, domain mutagenesis\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping, ISG15 conjugation assay, deconjugase competition; single lab with multiple complementary experiments\",\n      \"pmids\": [\"18413804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PML-RARA requires the methyltransferase activity of DNMT3A (but not DNMT3B) for aberrant self-renewal ex vivo, competitive transplantation advantage, and development of APL in vivo. DNMT3A is dispensable for RUNX1-RUNX1T1- and MLL-AF9-driven self-renewal, demonstrating a fusion-protein-specific epigenetic dependency.\",\n      \"method\": \"Retroviral expression of PML-RARA in DNMT3A-deficient mouse bone marrow cells, ex vivo self-renewal assays, competitive transplantation, Ctsg-PML-RARA transgenic mice on DNMT3A-null background\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple functional readouts (ex vivo, in vivo transplantation, leukemia development), fusion-specific controls included\",\n      \"pmids\": [\"26595813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"S100A3 calcium-binding protein directly interacts with RARα constitutively via the RARα ligand-binding domain (I396 residue is critical); this interaction controls the constitutive and ATRA-dependent degradation of RARα. In APL cells, S100A3 also interacts with PML-RARα; S100A3 knockdown decreases RARα levels and induces resistance to ATRA anti-proliferative effects in breast/lung cancer, while in APL/AML cells it increases basal and ATRA-induced differentiation.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis (I396), RARα interactome by LC-MS, knockdown and overexpression studies across multiple cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction confirmed by Co-IP and mutagenesis, functional consequences shown in multiple cell types; single lab\",\n      \"pmids\": [\"30532072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TNIP1 interacts with liganded RARα and RARγ via its NR boxes and requires the AF-2 domain of the receptor (characteristic of coactivators), but functionally represses RAR activity; repression is partially relieved by SRC1, suggesting TNIP1 interferes with coactivator recruitment. TNIP1 preferential interaction with RARα over RARγ maps to RARα LBD helices 5-9.\",\n      \"method\": \"Co-immunoprecipitation, domain mutagenesis, reporter gene assay, SRC1 competition assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and reporter assay, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"19732752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RARα forms a functional ternary complex with TDG (thymine DNA glycosylase) and CBP (histone acetylase). A TDG point mutation reducing ternary complex stability leads to deregulation of RA-target genes without affecting TDG's BER activity, demonstrating a direct coupling of TDG epigenomic function with RARα-dependent transcription.\",\n      \"method\": \"Co-immunoprecipitation, point mutagenesis of TDG, transcriptome profiling, reporter gene assay\",\n      \"journal\": \"Genomics, proteomics & bioinformatics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP and mutagenesis, global expression profiling; single lab, limited mechanistic depth\",\n      \"pmids\": [\"24394593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RARα-PLZF (reciprocal fusion from t(11;17)) inhibits myeloid differentiation by interacting with C/EBPα tethered to DNA, recruiting HDAC1, and causing histone H3 deacetylation at C/EBPα target loci, thereby decreasing C/EBPα target gene expression. HDAC inhibitors partially restore C/EBPα target gene expression.\",\n      \"method\": \"ChIP, DNA capture assays, HDAC inhibitor rescue, Co-immunoprecipitation with C/EBPα, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, DNA capture, pharmacological rescue, Co-IP; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"23898169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PML-RARα enhances constitutive autophagy by inhibiting the Akt/mTOR pathway; this autophagic upregulation is specific to PML-RARα and not observed with PLZF-RARα or NPM-RARα. Autophagy contributes to the anti-apoptotic function of PML-RARα, and autophagic flux assay revealed increased on-rate of autophagic sequestration.\",\n      \"method\": \"Transmission electron microscopy, autophagic flux assay, 3-methyladenine inhibitor, Western blot for Akt/mTOR pathway, inducible PML-RARα expression, leukemic mouse model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional readouts (TEM, flux assay, inhibitor, in vivo), pathway specificity confirmed with fusion protein comparisons; single lab\",\n      \"pmids\": [\"21673516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Ligand-free RARα maintains epigenetic memory by regulating CpG methylation status at specific promoters (e.g., Mest, Tex13); RARα-KO cells show increased promoter CpG methylation and H3K9me3 at repressed genes, and decreased methylation with increased H3K9/K14ac at activated genes. Stable PML-RARα expression recapitulates the Mest downregulation seen in RARα-KO cells, and specific RARα/RXRα association with the Mest promoter was demonstrated.\",\n      \"method\": \"Microarray expression analysis, ChIP (H3K9me3, H3K9/K14ac, H3K4me3), bisulfite sequencing, RARα-KO cells, PML-RARα stable transfection, Co-IP of RARα/RXRα at Mest promoter\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and bisulfite sequencing with genetic KO and fusion protein; single lab, multiple epigenetic marks\",\n      \"pmids\": [\"21911359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Intestinal epithelial cell-specific RARα signaling is required for proper epithelial lineage specification: RARα-deficient IECs show increased goblet cells and Paneth cells, increased KLF4+ goblet cell precursors, and an underdeveloped intestinal immune system (near-complete absence of lymphoid follicles and gut-resident mononuclear phagocytes). RA treatment inhibited klf4 expression and goblet cell differentiation in zebrafish, mechanistically linking RARα to KLF4 suppression.\",\n      \"method\": \"IEC-specific RARα conditional knockout mouse, zebrafish RA treatment/klf4 expression assay, histological analysis, infection clearance assay\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined cellular phenotype, zebrafish mechanistic validation; single lab\",\n      \"pmids\": [\"29139475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Myeloid RARα protects against atherosclerosis by inducing cholesterol efflux transporter expression (Abca1, Abcg1) and inhibiting inflammation. Myeloid-specific RARα ablation reduces macrophage Abca1/Abcg1 expression and cholesterol efflux, increases inflammatory genes, and aggravates Western diet-induced atherosclerosis in Ldlr−/− mice.\",\n      \"method\": \"Myeloid-specific RARα conditional knockout (Rarα-flox × LysM-Cre), macrophage lipid accumulation assay, cholesterol efflux assay, atherosclerosis plaque quantitation, ATRA treatment\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined mechanistic and phenotypic readouts; single lab\",\n      \"pmids\": [\"36291054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RARα supports Langerhans cell (LC) development from embryonic and bone marrow-derived progenitors by promoting expression of the LC-promoting transcription factor Runx3 and suppressing LC-inhibiting C/EBPβ. RARα promotes LC and langerin+ conventional DC development only under hypo-RA conditions, with this function suppressed at systemic RA levels.\",\n      \"method\": \"RARα conditional knockout, bone marrow-derived LC differentiation assays, Runx3 and C/EBPβ expression analysis, RA dose-response experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO, defined transcription factor targets, RA dose-response; single lab\",\n      \"pmids\": [\"30254197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PML-RARα acts through both repressive and activating transcriptional functions; the activating function involves recruiting P300 and forming super-enhancers. PML-RARα oligomers transactivate GFI1 through chromatin conformation changes at super-enhancers, and GFI1 is required for APL cell maintenance.\",\n      \"method\": \"ChIP-seq, Hi-C chromatin conformation, in vitro and in vivo functional assays, super-enhancer mapping\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq with super-enhancer mapping, chromatin conformation, functional in vivo validation; multiple orthogonal approaches\",\n      \"pmids\": [\"32854112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PML-RARα mediates extensive chromatin interactions genome-wide, redefining chromatin topology toward a more condensed configuration in APL cells. Locally, PML-RARα intrudes RNAPII-associated interaction domains, interrupts myeloid-specific transcription factor binding at enhancers and super-enhancers, and leads to transcriptional repression of myeloid differentiation genes.\",\n      \"method\": \"3D genome/Hi-C analysis of inducible PML-RARα system and patient-derived APL cells, ChIP-seq, RNA-seq\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible system plus patient cells, 3D genome, ChIP-seq, RNA-seq; multiple orthogonal genome-wide methods\",\n      \"pmids\": [\"32393309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"p97/VCP segregase is required for arsenic-induced degradation of PML-RARA and PML. After arsenic treatment, p97 localizes to PML nuclear bodies and extracts poly-ubiquitinated, poly-SUMOylated PML for proteasomal degradation; UFD1 and NPLOC4 cofactors of p97 are critical for this process.\",\n      \"method\": \"Proteomics of PML bodies, pharmacological p97 inhibition, siRNA depletion of p97/UFD1/NPLOC4, immunofluorescence, Western blot, PML body morphology analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomics, pharmacological inhibition, siRNA, imaging; multiple orthogonal approaches establishing the UFD1-NPLOC4-p97 mechanism\",\n      \"pmids\": [\"36880596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HDAC3 deacetylates PML-RARα at lysine 394, which reduces PIAS1-mediated PML-RARα SUMOylation and subsequent RNF4-induced ubiquitylation. HDAC3 inhibition promotes PML-RARα ubiquitylation and degradation in both wild-type and ATRA/ATO-resistant APL cells.\",\n      \"method\": \"Co-immunoprecipitation, deacetylation assay, SUMOylation assay, ubiquitylation assay, pharmacological HDAC3 inhibition, xenograft models, primary patient samples\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biochemical deacetylation/SUMOylation/ubiquitylation assays with site-specific mutant (K394), pharmacological and genetic validation in multiple models including patient samples\",\n      \"pmids\": [\"36894687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PML/RARα is neddylated in its RARα moiety; neddylation enhances PML/RARα DNA-binding ability and impedes phase separation of the PML moiety, disrupting PML nuclear body assembly. Deneddylation of PML/RARα restores its phase separation and reconstructs functional PML nuclear bodies; MLN4924 (neddylation inhibitor) eradicates APL cells in vitro and in vivo.\",\n      \"method\": \"Neddylation assay, DNA-binding assay, phase separation imaging, PML nuclear body reconstitution, MLN4924 pharmacological inhibition, in vitro and in vivo APL models\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical and imaging assays, pharmacological validation in vivo; single lab, phase separation mechanistic claim requires further independent validation\",\n      \"pmids\": [\"35194189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIB3 (pseudokinase) interacts with PML-RARα to inhibit PPARγ activity by disrupting the PPARγ/RXR interaction and promoting PPARγ degradation; reduced PPARγ activity in APL cells causes dyslipidemia. Arsenic/ATRA therapy degrades PML-RARα but elevates TRIB3, which then suppresses PPARγ/RXR dimerization, contributing to therapy-induced dyslipidemia.\",\n      \"method\": \"Co-immunoprecipitation, dual luciferase reporter assay, gene set enrichment analysis, Western blot, APL transgenic and transplantation mouse models, primary patient samples\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, reporter assay, multiple in vivo models; single lab\",\n      \"pmids\": [\"32929351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PML-RARα phosphorylation by PKA blocks its ability to inhibit PML oligomerization and destabilize HIPK2 at nuclear bodies; PML oligomerization and HIPK2 stabilization at nuclear bodies are both required for APL cell differentiation.\",\n      \"method\": \"Nuclear body disruption assay, PML oligomerization assay, HIPK2 stability assay, PKA phosphorylation assay, APL cell differentiation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical oligomerization and kinase assays with functional differentiation readout; single lab\",\n      \"pmids\": [\"23722549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"YOD1 deubiquitinase stabilizes PML/RARα by removing ubiquitin chains; siRNA-mediated YOD1 suppression promotes PML/RARα degradation and inhibits APL cells. The YOD1 inhibitor G5 degrades PML/RARα and eradicates APL cells including drug-resistant cells and patient-derived blasts.\",\n      \"method\": \"DUB siRNA library screen, siRNA knockdown of YOD1, ubiquitination assay, PML/RARα protein stability assay, APL cell and mouse model, primary patient blasts\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA screen, ubiquitination assay, in vivo validation; single lab\",\n      \"pmids\": [\"35847510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"USP37 deubiquitinase interacts with PLZF/RARA through the PLZF moiety and the N-terminal domain of USP37, sustaining PLZF/RARA steady-state levels by controlling its poly-ubiquitination. USP37 knockdown alleviates PLZF/RARA-mediated target gene suppression and cell transformation potential.\",\n      \"method\": \"RNAi screen, Co-immunoprecipitation, domain mapping, protein half-life assay, poly-ubiquitination assay, hematopoietic progenitor transformation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi screen, Co-IP, half-life and ubiquitination assays, functional transformation assay; single lab\",\n      \"pmids\": [\"23208507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PML-RARα directly represses S100A10 expression; ATRA-induced PML-RARα degradation rapidly downregulates S100A10 on the APL cell surface, reducing plasminogen receptor activity and fibrinolytic generation of plasmin at the cell surface. This provides a molecular link between PML-RARα expression and the hemorrhagic phenotype of APL.\",\n      \"method\": \"Flow cytometry for cell-surface S100A10, RNA interference knockdown of S100A10, inducible PML-RARα expression, fibrinolytic activity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible expression, siRNA, functional fibrinolytic assay; single lab\",\n      \"pmids\": [\"21310922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RAR alpha:RXR alpha heterodimers activate the rat Mrp2 (Abcc2) promoter; in obstructive cholestasis, cytokine (IL-1β)-dependent reduction of nuclear RAR alpha:RXR alpha levels and their binding to the Mrp2 promoter is associated with organ-specific suppression of hepatic Mrp2 expression while renal expression is preserved.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), immunoblot, ribonuclease protection assay, primary hepatocyte cytokine treatment, bile duct ligation model\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA demonstrating direct RARα:RXRα binding to Mrp2 promoter, in vivo and in vitro models; single lab\",\n      \"pmids\": [\"12145812\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RARA encodes a ligand-activated nuclear receptor that, when bound to all-trans retinoic acid, heterodimerizes with RXRα to bind retinoic acid response elements and activate transcription of target genes driving myeloid differentiation, cell cycle arrest (via C/EBPε→Mad1→p27 axis), and tissue homeostasis; in the absence of ligand, RARα recruits co-repressors (SMRT, N-CoR, HDACs) to suppress target genes. In acute promyelocytic leukemia, fusion of RARα to PML (or other partners) enforces homodimerization, dramatically expands DNA-binding site repertoire, recruits co-repressors with higher affinity independent of RA, and recruits HDAC3-MBD1 complexes to establish stable epigenetic silencing of myeloid differentiation genes; therapeutic doses of RA or arsenic trioxide relieve repression and trigger proteasomal degradation of the fusion protein through distinct mechanisms—RA targets the RARα moiety and arsenic triggers SUMO-dependent RNF4-mediated polyubiquitination of the PML moiety, with subsequent p97/VCP-UFD1-NPLOC4 extraction for proteasomal destruction—and it is PML-RARα loss, not merely transcriptional reactivation, that eradicates leukemia-initiating cells. Beyond transcription, RARα also functions as a translational repressor in neuronal RNA granules and, through Ser77 phosphorylation by CAK, modulates the balance between transcriptional repression and activation during differentiation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RARα is a ligand-activated nuclear receptor that heterodimerizes with RXRα on retinoic acid response elements to control gene programs of myeloid differentiation, cell-cycle arrest, and tissue homeostasis, acting bidirectionally to stimulate differentiation when bound to retinoic acid and to limit it in the unliganded state [#2]. Mechanistically, RARα drives granulocytic cell-cycle arrest through a RARα→C/EBPε→Mad1→p27(Kip1) axis [#12], and in the unliganded state maintains epigenetic memory by setting CpG methylation and histone-modification states at target promoters [#28]. Tissue-specific signaling further governs intestinal epithelial lineage specification via KLF4 suppression [#29], Langerhans cell development through Runx3 induction and C/EBPβ repression [#31], and macrophage cholesterol efflux gene expression [#30]. Beyond transcription, RARα associates with FMRP- and Purα-containing dendritic RNA transport granules, binds target mRNAs, and represses translation initiation independent of cap or poly(A) tail to drive retinoic-acid-stimulated dendritic growth [#3]. RARα activity is tuned by phosphorylation: CAK phosphorylation at Ser77 shifts the balance toward repression, while its loss couples G1 arrest to differentiation through coactivator exchange (N-CoR off, NCoA-3 on) [#15]. In acute promyelocytic leukemia, fusion of RARα to PML enforces homodimerization, which enhances corepressor (SMRT) binding and dramatically expands the DNA-binding site repertoire required for hematopoietic progenitor immortalization [#6]; the fusion recruits HDAC3-MBD1 complexes to establish spreading chromatin silencing of differentiation genes [#5] and additionally exerts P300-dependent activating functions through super-enhancer formation [#32], reorganizing genome-wide chromatin topology toward a repressive configuration [#33]. Therapeutic response depends on destruction of the fusion protein, not merely transcriptional reactivation [#8]: retinoic acid targets the RARα moiety while arsenic triggers SUMO-dependent RNF4-mediated polyubiquitination of the PML moiety [#1], with subsequent p97/VCP-UFD1-NPLOC4 extraction for proteasomal degradation [#34].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that the defining oncogenic lesion of APL acts by aberrant transcriptional repression, reframing the disease as an epigenetic differentiation block reversible by combining HDAC inhibition with retinoic acid.\",\n      \"evidence\": \"Transgenic mouse models with co-repressor interaction assays and HDAC inhibitor rescue for PML-RARα and PLZF-RARα\",\n      \"pmids\": [\"9462740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the specific HDAC-containing complexes or genomic targets\", \"Mechanism of RA resistance only attributed to PLZF moiety, not molecularly resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined endogenous RARα as a modulatory rather than obligatory regulator of granulopoiesis, distinguishing its normal physiological role from the dominant block imposed by fusion proteins.\",\n      \"evidence\": \"RARα knockout mice, vitamin A-deficiency model, and RAR antagonist treatment with granulocyte differentiation assays\",\n      \"pmids\": [\"11222375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct transcriptional targets driving the modulatory effect\", \"Redundancy with other RAR isotypes not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapped the cell-cycle arrest arm of RARα differentiation signaling to a defined transcription factor cascade, placing RARα upstream of an indirect C/EBPε→Mad1→p27 pathway.\",\n      \"evidence\": \"Primary cells from p27 and Mad1 knockout mice, isoform-specific agonists, and ChIP of C/EBPε at the Mad1 promoter\",\n      \"pmids\": [\"14576045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RARα target genes between RARα and C/EBPε not fully enumerated\", \"Did not address contribution of this axis in fusion-driven leukemia\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved how PML-RARα homodimerization confers gain-of-function, showing it both enhances corepressor binding and relaxes DNA-site specificity to enable hematopoietic immortalization, and identified the HDAC3-MBD1 complex as the silencing effector.\",\n      \"evidence\": \"Dimerization/DNA-binding domain mutagenesis with primary progenitor immortalization, plus ChIP, RNAi and dominant-negative MBD1 rescue\",\n      \"pmids\": [\"16757557\", \"16432238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full genomic catalog of expanded binding sites not defined at this stage\", \"How HDAC3-MBD1 spreading is initiated and bounded unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that arsenic therapy works by catabolizing the fusion protein, defining SUMOylation of the PML moiety and RNF4-mediated ubiquitination as the degradation trigger required for differentiation.\",\n      \"evidence\": \"Co-IP, non-degradable SUMO mutant, dominant-negative RNF4, and proteasome inhibition in APL cells\",\n      \"pmids\": [\"18408733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the segregase/extraction machinery downstream of ubiquitination\", \"Relationship to the parallel RA-induced degradation pathway not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended RARα function beyond transcription by identifying a translational repressor role in neuronal dendritic RNA granules, providing a mechanism for rapid retinoic-acid-stimulated dendritic growth.\",\n      \"evidence\": \"LC/MS immunoaffinity isolation, TAP, confocal microscopy, in vitro translation assays and RARα knockdown in hippocampal neurons\",\n      \"pmids\": [\"18495661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of RARα mRNA binding not defined\", \"Generality across other neuronal mRNAs and cell types untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Separated transcriptional reactivation from protein clearance, proving that PML-RARα degradation, not differentiation induction per se, is required to eradicate leukemia-initiating cells.\",\n      \"evidence\": \"Uncoupling synthetic retinoids in a mouse APL transplantation model with secondary transplantation of sorted differentiated cells\",\n      \"pmids\": [\"23509325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis distinguishing transcriptional from degradative activity of retinoids not detailed\", \"Did not address whether arsenic-mediated clearance behaves identically\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that APL differentiation is a default program released by clearing the fusion from chromatin, with RXRA required both for transformation and for the fusion's tight DNA binding.\",\n      \"evidence\": \"Genetic RXRA ablation with ex vivo and in vivo differentiation assays and sumoylation mutant analysis\",\n      \"pmids\": [\"25258343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which RXRA loss loosens DNA binding not structurally defined\", \"Role of RXRA sumoylation in transformation only partially mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified a fusion-protein-specific epigenetic dependency, showing PML-RARA uniquely requires DNMT3A methyltransferase activity for self-renewal and leukemogenesis.\",\n      \"evidence\": \"PML-RARA expression in DNMT3A-deficient bone marrow, competitive transplantation, and Ctsg-PML-RARA transgenic mice on DNMT3A-null background\",\n      \"pmids\": [\"26595813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific DNMT3A target loci enforcing self-renewal not identified\", \"Mechanistic link between DNMT3A and HDAC3-MBD1 silencing unexplored\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed that PML-RARα reshapes 3D genome topology and possesses an activating, super-enhancer-forming function alongside repression, broadening the oncogenic mechanism beyond simple corepressor recruitment.\",\n      \"evidence\": \"ChIP-seq, Hi-C and super-enhancer mapping in inducible and patient-derived APL cells with in vivo functional validation of GFI1\",\n      \"pmids\": [\"32854112\", \"32393309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single fusion both activates super-enhancers and represses differentiation loci mechanistically unresolved\", \"Determinants of locus-specific activation versus repression not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Completed the arsenic-induced degradation pathway by identifying the p97/VCP segregase and its UFD1-NPLOC4 cofactors as the machinery that extracts ubiquitinated, SUMOylated PML-RARA from nuclear bodies for proteasomal destruction.\",\n      \"evidence\": \"PML-body proteomics, p97 pharmacological inhibition, siRNA depletion of p97/UFD1/NPLOC4, and imaging\",\n      \"pmids\": [\"36880596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p97 also participates in RA-induced RARα-moiety degradation untested\", \"Stoichiometry and timing of extraction relative to RNF4 action unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the multiple post-translational modification systems controlling RARα/fusion stability (SUMO, ubiquitin, ISG15, NEDD8, acetylation, phosphorylation) are integrated and prioritized to determine therapeutic protein clearance.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking the competing modification pathways\", \"Relative contribution of each pathway to durable leukemia eradication unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 6, 12, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [6, 13, 16, 28, 42]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 28, 34]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [5, 6, 32]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 12, 32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 28, 33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 8, 22]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 34, 35]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 29, 31]}\n    ],\n    \"complexes\": [\n      \"RARα-RXRα heterodimer\",\n      \"PML-RARα fusion oncoprotein\",\n      \"HDAC3-MBD1 corepressor complex\"\n    ],\n    \"partners\": [\n      \"RXRA\",\n      \"PML\",\n      \"SMRT\",\n      \"HDAC3\",\n      \"NCOR2\",\n      \"FMRP\",\n      \"S100A3\",\n      \"EP300\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}